IMV - IMV makes interim CEO Andrew Hall permanent

IMV (NASDAQ:IMV) has appointed Andrew Hall as Chief Executive Office and Director of the Board, effective January 1, 2022. Chief Executive Officer of IMV, “There is significant potential for IMV and the DPX platform to deliver differentiated therapies to treat a broad range of cancers. IMV is ending 2021 in a strong position. We have achieved our recent milestones, which included compelling clinical and translational data in two Phase 2 trials; initiated several new trials in the last month; and have submitted our Phase 2b protocol for our ovarian cancer program to the FDA. We have also lengthened our financial runway and are well-positioned to execute upon our vision for IMV as we move into 2022.” Shares down 3.5% premarket. Yesterday, the company finalized basket study in collaboration with Merck in bladder cancer, solid tumors.

For further details see:

IMV makes interim CEO Andrew Hall permanent